产品详情
简单介绍：
Anti-LRFN1抗体产品质量稳定，实验效果明显，货期快，价格优惠，欢迎垂询订购！我公司长期供应**组化抗体、WB抗体、**组化试剂盒和抗体试验所需全部相关试剂、荧光标记抗体、单克隆抗体、多克隆抗体、各种标记的二抗IgG/IgM/IgD/IgA等科研实验抗体。Anti-LRFN1抗体用于**组化实验,WB实验,相应的标记抗体有HRP标记抗体,FITC标记,BIO等。
详情介绍：
Rabbit Anti-LRFN1
Cat. Number:
Anti-LRFN1抗体KL-12141R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
LRFN1 is a 771 amino acid single-pass type I membrane protein that belongs to the LRFN family. Containing a fibronectin type-III domain, an Ig-like (immunoglobulin-like) domain, a LRRCT domain, a LRRNT domain and seven LRR (leucine-rich) repeats, LRFN1 is thought to promote neurite outgrowth in hippocampal neurons and is involved in the regulation and maintenance of excitatory synapses. LRFN1 forms heteromeric
Anti-LRFN1抗体complexes with LRFN2, LRFN3, LFRN4 and LFRN5, but does not have the ability to form homomeric complexes across cell junctions of adjacent cells like other LRFN family members. The PDZ-binding motif of LRFN1 is required for neurite outgrowth promotion and for SAP 97-, NE-dlg- and PSD-95-binding. LRFN1 is encoded by a gene located on human chromosome 19q13.2 and mouse chromosome 7 A3.
Also known as:
Leucine rich repeat and fibronectin type III domain containing 1; Leucine rich repeat and fibronectin type III domain containing protein 1;
Anti-LRFN1抗体Leucine-rich repeat and fibronectin type III domain-containing protein 1; LRFN 1; lrfn1; LRFN1_HUMAN; SALM 2; SALM2; Synaptic adhesion like molecule 2; Synaptic adhesion-like molecule 2.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Dog, Pig, Cow, Sheep, .
●
Immunogen: KLH conjugated synthetic
Anti-LRFN1抗体peptide derived from human LRFN1.
●
Predicted Molecular Weight: 79kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500
Anti-LRFN1抗体
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
